Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 5,000 shares of Avidity Biosciences stock in a transaction that occurred on Friday, April 19th. The stock was sold at an average price of $22.82, for a total transaction of $114,100.00. Following the completion of the transaction, the director now directly owns 14,830 shares in the company, valued at approximately $338,420.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Avidity Biosciences Trading Up 4.1 %
Shares of RNA stock opened at $25.14 on Wednesday. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -8.67 and a beta of 0.77. Avidity Biosciences, Inc. has a 1-year low of $4.82 and a 1-year high of $27.66. The stock’s fifty day simple moving average is $21.51 and its 200-day simple moving average is $12.98.
Avidity Biosciences (NASDAQ:RNA – Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.25). The business had revenue of $2.19 million for the quarter, compared to analyst estimates of $32.08 million. Avidity Biosciences had a negative return on equity of 39.74% and a negative net margin of 2,219.87%. On average, sell-side analysts predict that Avidity Biosciences, Inc. will post -3.07 EPS for the current year.
Wall Street Analysts Forecast Growth
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Avidity Biosciences by 4.6% during the third quarter. FMR LLC now owns 11,114,431 shares of the biotechnology company’s stock valued at $70,910,000 after purchasing an additional 491,567 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Avidity Biosciences by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,014,490 shares of the biotechnology company’s stock valued at $25,612,000 after buying an additional 47,305 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Avidity Biosciences by 73.3% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,300,000 shares of the biotechnology company’s stock worth $8,294,000 after buying an additional 550,000 shares during the last quarter. Alethea Capital Management LLC raised its position in Avidity Biosciences by 0.6% during the third quarter. Alethea Capital Management LLC now owns 854,651 shares of the biotechnology company’s stock valued at $5,453,000 after acquiring an additional 5,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Avidity Biosciences by 6.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 545,771 shares of the biotechnology company’s stock valued at $4,939,000 after acquiring an additional 30,674 shares in the last quarter.
Avidity Biosciences Company Profile
Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Read More
- Five stocks we like better than Avidity Biosciences
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Lockheed Martin Stock Aims for a Fresh All-Time High
- How to Read Stock Charts for Beginners
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.